Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Ovarian Cancer Recurrence. A Review

Abstract Ovarian cancer is the first cause of death among gynecological malignancies with a high incidence of relapse in the first 3 years after initial operation. The 3 most common cause of relapse is the chemoresistance of the tumor, the biological behavior of the tumor and the third is the inappropriate surgical excision. Over the last years one of the most intriguing method in different cancer centers is the CRS+HIPEC. We present herein the different option concerning the role of this procedure. We declares the 2 different options of relapse disease as ’’residual’’ which means not complete surgical procedure in the initial operation, and real ’’recurrent’’ disease. The improvement in overall survival was maintained significant in HIPEC groups when compared to protocols without HIPEC. In conclusion Hipec seems to be beneficial to prolong survival in patients with relapse disease. Keywords: Hyperthermic intraperitoneal chemotherapy (HIPEC), epithelial ovarian cancer (EOC), Cytoreduction (CRS).